ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Kansas City, KS

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Kansas City, KS, USA:

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (RAINFOL-02)

study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already ...

Enrolling
Platinum-resistant Ovarian Cancer
Drug: Topotecan
Drug: Gemcitabine

Phase 3

Genmab
Genmab

Overland Park, Kansas, United States and 37 other locations

and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian ...

Enrolling
Ovarian Cancer
Cholangiocarcinoma Recurrent
Biological: SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR

Phase 1

Verismo Therapeutics

Westwood, Kansas, United States and 3 other locations

Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin A...

Enrolling
Stage IV Primary Peritoneal Cancer
Stage III Ovarian Cancer
Other: No treatment
Drug: Cisplatin

Phase 3

GOG Foundation

Kansas City, Kansas, United States and 50 other locations

ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian....

Active, not recruiting
Neoplasms, Ovarian
Drug: Topotecan
Drug: Paclitaxel

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Kansas City, Kansas, United States and 52 other locations

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors...

Enrolling
Uterine Cancer
Hormone Receptor-positive/Her2 Negative Breast Cancer
Drug: Carboplatin
Drug: Pembrolizumab

Phase 1, Phase 2

Genmab
Genmab

Westwood, Kansas, United States and 36 other locations

following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based...

Active, not recruiting
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Drug: Placebo Oral Tablet
Drug: Nivolumab

Phase 3

pharmaand

Westwood, Kansas, United States and 237 other locations

ultralow dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma ba...

Enrolling
Platinum-resistant Ovarian Cancer
Endometrial Adenocarcinoma
Diagnostic Test: OncoSignature
Drug: ACR-368

Phase 1, Phase 2

Acrivon Therapeutics

Kansas City, Missouri, United States and 66 other locations

The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall surviva...

Active, not recruiting
Ovarian Neoplasm
Fallopian Tube Neoplasms
Drug: Relacorilant 150 mg once daily (QD)
Drug: Nab-paclitaxel 100 mg/m^2

Phase 3

Corcept Therapeutics
Corcept Therapeutics

Overland Park, Kansas, United States and 116 other locations

as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high fola...

Enrolling
Peritoneal Cancer
Fallopian Tube Cancer
Drug: Bevacizumab
Drug: Mirvetuximab soravtansine plus Bevacizumab

Phase 3

AbbVie
AbbVie

Westwood, Kansas, United States and 289 other locations

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like you...

Enrolling
Other Solid Tumors
Ovarian Neoplasms
Drug: PF-08052666

Phase 1

Seagen, a wholly owned subsidiary of Pfizer

Kansas City, Kansas, United States and 18 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems